SYBX

Synlogic Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$7.78M
P/E Ratio
EPS
$-0.06
Beta
0.52
52W High
$1.96
52W Low
$0.54
50-Day MA
$0.64
200-Day MA
$1.10
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic drugs to treat cancer, inflammatory, and metabolic diseases in the United States. The company is headquartered in Cambridge, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-3.19M
Operating Margin0.00%
Return on Equity-8.17%
Return on Assets-12.50%
Revenue/Share (TTM)$0.00
Book Value$1.01
Price-to-Book0.61
Price-to-Sales (TTM)936.86
EV/Revenue0.349
EV/EBITDA0.18
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-100.00%
Shares Outstanding$11.70M
Float$3.48M
% Insiders22.60%
% Institutions35.28%

Historical Volatility

HV 10-Day
12.18%
HV 20-Day
34.11%
HV 30-Day
28.37%
HV 60-Day
49.49%
HV Rank

Volatility is currently contracting

Latest News

SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Synlogic, Inc. (OTC: SYBX) and Caldera Therapeutics, Inc. Upon closing of the proposed transaction, Synlogic shareholders are expected to own approximately 2.3% of the combined company. Halper Sadeh encourages Synlogic shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or.

Business Wire8/10/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SYBX and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 5/29/2026